Kathryn I Pollak1,2, Laura J Fish3,4, Linda M Sutton5,6, Xiaomei Gao3, Pauline Lyna3, Lynda Owen5, Michele L Patel7, Tamara J Somers3,8. 1. Cancer Control and Population Sciences, Duke Cancer Institute, Durham, NC, USA. kathryn.pollak@duke.edu. 2. Department of Population Health Sciences, Duke School of Medicine, 2424 Erwin Road, Suite 602, Durham, NC, 27705, USA. kathryn.pollak@duke.edu. 3. Cancer Control and Population Sciences, Duke Cancer Institute, Durham, NC, USA. 4. Department of Medicine, Duke School of Medicine, Durham, NC, USA. 5. Duke Cancer Network, Duke Cancer Institute, Durham, NC, USA. 6. Department of Psychology and Neuroscience, Duke School of Medicine, Durham, NC, USA. 7. Department of Psychiatry and Behavioral Sciences, Duke School of Medicine, Durham, NC, USA. 8. Faculty Practice in Psychiatry Erwin Square, Duke School of Medicine, 2200 W. Main Street Suite 340, Durham, NC, 27705, USA.
Abstract
PURPOSE: Many cancer survivors continue to smoke. Further, most survivors also report high levels of persistent pain and smoke in response to pain. The investigators tested the feasibility, acceptability, and preliminary efficacy of a smoking cessation program paired with a pain management programfor cancer survivors. METHODS: The investigators conducted a two-arm, wait-list randomized controlled pilot study in which they delivered a combined smoking cessation and pain management intervention. RESULTS: The investigators randomized 30 survivors (14 intervention and 16 wait-list control). Seventy-one percent of the survivors who received the intervention rated it as extremely useful (5 out of 5) in helping them quit smoking. Further, 86% would recommend the program to other survivors. Although we could not conduct inferential statistics, 14% of those in the intervention arm, compared to 6% in the control condition had biochemically validated cessation at 2-months post-randomization. Survivors in the intervention also reported less pain, had improvements in depressive symptoms, and better physical function than those in the control arm. CONCLUSIONS: Our pilot data suggest the feasibility, acceptability, and preliminary efficacy of this approach. The next step is to conduct a large randomized controlled trial to fully test the efficacy of the intervention. IMPLICATIONS FOR CANCER SURVIVORS: A combined smoking cessation and pain program might help improve both issues simultaneously.
RCT Entities:
PURPOSE: Many cancer survivors continue to smoke. Further, most survivors also report high levels of persistent pain and smoke in response to pain. The investigators tested the feasibility, acceptability, and preliminary efficacy of a smoking cessation program paired with a pain management program for cancer survivors. METHODS: The investigators conducted a two-arm, wait-list randomized controlled pilot study in which they delivered a combined smoking cessation and pain management intervention. RESULTS: The investigators randomized 30 survivors (14 intervention and 16 wait-list control). Seventy-one percent of the survivors who received the intervention rated it as extremely useful (5 out of 5) in helping them quit smoking. Further, 86% would recommend the program to other survivors. Although we could not conduct inferential statistics, 14% of those in the intervention arm, compared to 6% in the control condition had biochemically validated cessation at 2-months post-randomization. Survivors in the intervention also reported less pain, had improvements in depressive symptoms, and better physical function than those in the control arm. CONCLUSIONS: Our pilot data suggest the feasibility, acceptability, and preliminary efficacy of this approach. The next step is to conduct a large randomized controlled trial to fully test the efficacy of the intervention. IMPLICATIONS FOR CANCER SURVIVORS: A combined smoking cessation and pain program might help improve both issues simultaneously.
Authors: W Michael Hooten; Kristin S Vickers; Yu Shi; Kaye L Ebnet; Cynthia O Townsend; Christi A Patten; David O Warner Journal: Pain Pract Date: 2011-04-25 Impact factor: 3.183
Authors: W Michael Hooten; Cynthia O Townsend; J Taylor Hays; Kaye L Ebnet; Thomas R Gauvin; Jessica M Gehin; Heidi J Laures; Christi A Patten; David O Warner Journal: Addict Behav Date: 2013-11-21 Impact factor: 3.913
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Alexander L Patterson; Susan Gritzner; Michael P Resnick; Steven K Dobscha; Dennis C Turk; Benjamin J Morasco Journal: J Pain Date: 2012-02-09 Impact factor: 5.820
Authors: Robert A Schnoll; Elisa Martinez; Kristina L Tatum; Dorothy M Weber; Natalie Kuzla; Marcella Glass; John A Ridge; Corey Langer; Curtis Miyamoto; E Paul Wileyto; Frank Leone Journal: Cancer Causes Control Date: 2010-01-20 Impact factor: 2.506
Authors: Johan S Rietman; Pieter U Dijkstra; Rolanda Debreczeni; Jan H B Geertzen; Douglas P H Robinson; Jaap De Vries Journal: Disabil Rehabil Date: 2004-01-21 Impact factor: 3.033